Oct 16, 2024
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences
Oct 15, 2024
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Oct 14, 2024
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Oct 08, 2024
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
Sep 20, 2024
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
Sep 18, 2024
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
Sep 09, 2024
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
Aug 19, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Jun 03, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
Mar 27, 2024
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
Feb 14, 2024
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
Feb 12, 2024
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer
Feb 12, 2021
Kintara Therapeutics Announces Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update
Jan 13, 2021
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial
Jan 05, 2021
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
Dec 03, 2020
Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit
Nov 19, 2020
Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study
Nov 13, 2020
Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates
Sep 21, 2020
Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates
Sep 01, 2020
Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million